文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

PRODIG研究:短期维格列汀治疗预防肾移植术后早期新发糖尿病的随机对照研究方案

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.
PubMed 文献 · Trials · 2019-06-21

本研究为多中心、双盲、安慰剂对照随机临床试验,纳入法国十家移植中心首次肾移植患者,按1:1随机接受维格列汀(根据肾小球滤过率100或50 mg/天)或安慰剂治疗2个月,主要结局为移植后1年糖尿病比例。

要点

  • 移植后糖尿病是肾移植常见严重并发症,目前无预防或延迟该病的治疗。
  • 高危患者短期使用维格列汀可能预防移植后新发糖尿病。
  • 主要结局为移植后1年糖尿病比例,次要结局包括糖化血红蛋白、急性排斥、感染、移植物丢失和患者死亡。

核心结论

  • 研究者假设短期维格列汀治疗可能预防高危患者移植后新发糖尿病,若假设验证,结果将直接应用于临床实践。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机临床试验,纳入法国十家移植中心首次肾移植患者。
  • 纳入患者按1:1随机接受维格列汀100或50 mg/天(取决于肾小球滤过率)或安慰剂治疗2个月,首剂在进入手术室前给药。

主要发现

  • 主要结局为移植后1年糖尿病比例,定义为接受糖尿病治疗、空腹血糖高于7 mmol/l和/或口服葡萄糖耐量试验异常。
  • 次要结局包括移植后3个月、6个月和12个月的糖化血红蛋白、急性排斥、感染、移植物丢失和患者死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease. Nevertheless, identification of risk factors make it possible to target a population at risk of developing de novo diabetes. We hypothesized that a short-term treatment with vildagliptin may prevent new onset diabetes after transplantation (NODAT) in high-risk patients. METHODS/DESIGN: This is a multicenter, double-blind, placebo-controlled randomized clinical trial. Patients undergoing first kidney transplantation will be included from ten French transplant centers. Included patients will be randomized (1:1) to receive either vildagliptin 100 or 50 mg/day (depending on glomerular filtration rate) during 2 months (the first dose being administered before entering the operating theatres) or placebo. Additional antidiabetic therapy could be administered according to glycemic control. The primary outcome is the proportion of diabetic patients 1 year after transplantation, defined as patients receiving a diabetic treatment, or having a fasting glucose above 7 mmol/l, and/or with an abnormal oral glucose tolerance test. Secondary outcomes include glycated hemoglobin, the occurrence of acute rejection, infection, graft loss and patient death at 3 months, 6 months, and 12 months after transplantation. Outcomes will be correlated to clinical and general characteristics of the patient, cardiovascular history, nephropathy, dialysis history, transplantation data, biological data, health-related quality of life, and the cost-effectiveness of prevention of diabetes with vildagliptin. DISCUSSION: We have scarce data on the pharmacological prevention of post-transplant diabetes. If our hypothesis is verified, our results will have a direct application in clinical practice and could limit diabetes-associated morbidity, reduce cardiovascular complications, increase quality of life of renal transplant patients, and consequently promote graft and patient survival. Our results may possibly serve for non-transplant patients carrying a high-risk of diabetes associated with other co-morbidities. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02849899 . Registered on 8 February 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gaiffe E, Crepin T, Bamoulid J, et al. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. Trials. 2019. PMID: 31227028. doi:10.1186/s13063-019-3392-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。